These contracts are with existing clients and have a minimum value of $635,000 and $200,000 respectively. They bring the total value of US pharmaceutical clinical trials contracts secured over the past 10 months to $7.3 million.
Duncan Ross, CEO of AtCor Medical, said: “These contracts from existing customers to support new clinical trials demonstrate the importance of noninvasive central blood pressure data in drug development and the high quality of the services we provide.”